P. Papathanassopoulos

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

Action and object naming in schizophrenia

M. Kambanaros, L. Messinis, P. Papathanassopoulos, 2010, Journal of clinical and experimental neuropsychology.

Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study

A. Kyritsis, S. Deftereos, A. Tavernarakis, 2018, BMC Neurology.

The role of postoperative radiotherapy in the management of patients with thymic tumors -- a retrospective study.

V. Vassiliou, D. Kardamakis, A. Tsamandas, 2009, In vivo.

Immunotherapy for multiple sclerosis: basic insights for new clinical strategies.

Theodore V. Tselios, A. Mouzaki, P. Papathanassopoulos, 2004, Current neurovascular research.

Leptin and its soluble receptor in plasma of patients suffering from remitting-relapsing multiple sclerosis (MS) In vitro effects of leptin on type-1 and type-2 cytokine secretion by peripheral blood mononuclear cells, T-cells and monocytes of MS patients.

A. Mouzaki, P. Papathanassopoulos, K. Chatzantoni, 2004, Journal of autoimmunity.

Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators.

Vasso Apostolopoulos, Francesco Lolli, Theodore V. Tselios, 2005, Journal of medicinal chemistry.